Arcus Biosciences, Inc. — Director's Dealing 2021

Jun 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2021-06-03

Reporting Person: Lacey David L. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-03	Common Stock	A	3000	$0.00	Acquired	38352	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-03	Stock Option (Right to Buy)	$24.79	A	14100	Acquired	2031-06-02	Common Stock (14100)	Direct

Footnotes

F1: Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

F2: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control.